Biopharma teams don’t lose deals because they lack ambition. They lose because they’re late.
In licensing, partnering, and BD strategy, timing is everything—especially when the “product” isn’t just a molecule, but the entire go-to-market package around…

Biosimilar timelines are won—or lost—before the public “launch window” ever shows up.
Most teams treat patent expiry intelligence like a calendar exercise: identify the date, map the patents, and wait for the moment the market opens. That approach is…

Europe’s drug patent clock is ticking—and most people misunderstand where it actually stops.
In Europe, the question isn’t simply “How long is patent protection?” It’s “How long does protection really last in practice—and what breaks first?”
Drug p…

Drug discovery is stuck in traffic—and the clock is the loudest honk in the room.
From target identification to lead optimization, the timeline is long, expensive, and increasingly unforgiving. Every delay compounds: data arrives late, experiments repe…

The “patent cliff” isn’t a cliff anymore—it’s a calendar.
For years, commercial market access teams have treated generic entry as a sudden event: a date on a slide, a scramble in the final quarter, and then—inevitably—margin compression. But the indu…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage in pharma isn’t just about winning the patent fight—it’s about what happens after the win.
For years, the market narrative has been straightforward…

The clock is ticking—and “true generic” timing can make or break value.
In generic drugs, everyone talks about exclusivity. Fewer people talk about timing mechanics—the exact moment a product can legally enter, and how regulatory exclusivities interact…

The real “patent war” isn’t fought in court—it’s fought in the months before the drug goes generic.
Generic entry is often framed as a simple timeline: patent expires, competition arrives, prices fall. But anyone who’s watched the Paragraph IV process …